Key Drivers
- Very high gross-margin
- Significant net debt
- Elevated valuation multiples
AIAI Summary
Amicus has shifted from a high‑burn biotech to a cash‑generating, high‑margin commercial franchise whose near‑term value is now driven more by acquisition arbitrage and execution on Galafold/Pombiliti scale than by pipeline upside. Monitor BioMarin deal closure and litigation, quarterly revenue/FCF and COGS trends, and debt coverage—any setback could quickly remove the premium, while clean deal close and sustained margins justify upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross-margin
- •Significant net debt
- •Elevated valuation multiples
FOLD combines very strong gross margins and positive operating cash flow with heavy operating spend, material leverage, recurring net losses, and an elevated valuation.
Price Behavior
Key Price Behavior Insights:
- •Tight range
- •Very low volatility
- •Defined support
Over the last month the stock traded flat-to-slightly-up (≈0.6% to $14.43) within a tight $14.33–$14.38 range, showing very low volatility and well-defined support that keeps it range-bound absent a volume-backed breakout.
Repeated identical closes and muted excursions indicate unusually low short-term price dispersion
Sentiment & News
Key News Insights:
- •Revenue beat
- •Acquisition $4.8B
- •Institutional trimming
Amicus beat Q4 revenue on Galafold/Pombiliti but missed EPS, is being acquired by BioMarin for $4.8B, and saw institutional trimming despite the deal and revenue strength.
Deal-driven dynamics and ongoing selling pressure likely limit near-term upside despite commercial strength
Similar Companies in Healthcare
Other companies in the same sector with AI ratings